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Abstract
Background: The aim of this study was to evaluate the potential association between single nucleotide
polymorphisms related response to radiotherapy injury, such as genes related to DNA repair or enzymes involved
in anti-oxidative activities. The paper aims to identify marker genes able to predict an increased risk of late toxicity
studying our group of patients who underwent a Single Shot 3D-CRT PBI (SSPBI) after BCS (breast conserving
surgery).
Methods: A total of 57 breast cancer patients who underwent SSPBI were genotyped for SNPs (single nucleotide
polymorphisms) in XRCC1, XRCC3, GST and RAD51 by Pyrosequencing technology. Univariate analysis (ORs and
95% CI) was performed to correlate SNPs with the risk of developing ≥ G2 fibrosis or fat necrosis.
Results: A higher significant risk of developing ≥ G2 fibrosis or fat necrosis in patients with: polymorphic variant
GSTP1 (Ile105Val) (OR = 2.9; 95%CI, 0.88-10.14, p = 0.047).
Conclusions: The presence of some SNPs involved in DNA repair or response to oxidative stress seem to be able
to predict late toxicity.
Trial Registration: ClinicalTrials.gov: NCT01316328
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Background
Conservative surgery followed by adjuvant radiotherapy
(RT) to whole breast has become widely accepted as a
standard of care for women with early breast cancer. In
particular, a number of studies [1-4] reported that most
(81%-100%) intra breast tumour recurrences after breast
conserving surgery (BCS) occur in close proximity to
the tumour bed, so providing the rationale of Partial
Breast Irradiation (PBI) an adjuvant RT limited to the
Index Area i.e. the area of breast only including the pri-
mary tumour bed and the surrounding tissue. In addi-
tion, the delivery of radiation dose to smaller target
volume by PBI is expected to reduce radiation-related
toxicity. Thus, the so-called Accelerated Partial Breast
Irradiation (APBI), where only the Index Area is irra-
diated in 1-10 fractions at high dose/fraction, has been
promoted in phase I-III trials designed to test feasibility
and equivalence with standard Whole Breast Irradiation
(WBI) in properly selected low risk early breast cancer
patients after BCS [5]. However, a remarkably high rate
of late toxicity has been reported by some Authors a
few years after follow up with this APBI approach [6,7].
A high late toxicity rate was also observed in our cohort,
after single shot of PBI (SSPBI) [8]. Thus the possibility
to predict patient outcome based on marker genes cor-
related with radio-induced toxicity was investigated.
The interaction of RT with living tissue generates,
directly or transitorily, reactive oxygen species (ROS)
triggering a series of inflammation reactions. Adaptation
to oxidative stress occurs by activating genes that char-
acterize the cellular responses to this type of stress and
generates a series of processes including DNA repair
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pathways, cell cycle arrest, antioxidant enzymes and
secretion of cytokines that are suspected to play a cen-
tral role in the development of mainly late normal tissue
damage [9,10]. These mechanisms, eventually lead to
avoiding extensive DNA damage, cell death [11], and
inflammatory process, that may enhance ROS produc-
tion, thus, contributing to the formation of fibrogenesis
and tissue remodelling [12]. In particular, Glutathione-
S-Transferase (GSTs) are antioxidant enzymes which are
classified into the following classes: alpha (GSTA), mu
(GSTM), pi (GSTP), theta, sigma, and kappa. Under con-
ditions of stress the GSTP1 class is implicated in pro-
apoptotic signalling and may mediate cytotoxicity
[13-15]. Two independent studies recently carried out
on BC patients have reported a significant association
between the GSTP1 105Val variant (313 G) and an
increased risk of developing acute or late adverse reac-
tions induced by radiation therapy [9,16].
In addition, XRCC1 (X-ray Repair Cross-Complemen-
tation group 1), XRCC3 (X-ray Repair Cross-Comple-
mentation group 3) RAD51, genes involved in the DNA
repair process may influence susceptibility to side effects
in patients receiving radiation therapy given that DNA
is a direct target for ionizing radiation [17-20].
Various studies [21-23] showed a significant associa-
tion between the polymorphic nature of these genes and
the possibility of developing biomarkers or predictive
assay for radio-sensitivity in breast cancer patients.
To correlate the genetic variation and association
between the development of late effects [24,25], we
investigated the following specific polymorphic genes:
XRCC1 (Arg399Gln), XRCC3 (5’UTR and Thr241Met),
GSTP1 (Ile105Val) and RAD51.
Methods
From March 2006 to January 2008, patients who under-
went BCS and a sentinel node biopsy and/or axillary
dissection for early breast adenocarcinoma and met elig-
ibility criteria were treated in the prone position with an
adjuvant single dose 3D-CRT APBI schedule to the
Index Area. The eligibility criteria included being aged ≥
48 years with a life expectancy of at least 5 years, post-
menopausal status, histologically proved cancer, non
lobular, adenocarcinoma of the breast, primary tumours
≤ 3 cm, negative surgical margins (≥ 2 mm), negative
sentinel nodes or < 4 positive axillary nodes, no extra-
capsular extension, no previous radiotherapy. The exclu-
sion criteria included patients with multicentric disease,
extended intraductal component (EIC > 25%), Paget’s
disease of the nipple, lobular adenocarcinoma, and dis-
tant metastases.
A dose of 18 (in 4 patients) or 21 Gy (in 60 patients),
normalized to the PTV mean dose, was prescribed in a
single session. Major technical details of our approach
have been previously reported in detail in a distinct
paper [26]. Some radiobiological considerations on sin-
gle dose, time factors, clonogenic cell density and dose
constraints are reported in distinct papers [27-30].The
study was conducted in accordance with the Helsinki
Declaration. Each patient was informed about the study
protocol in both verbally and in writing (informed con-
sent) in advance. The patient was given ample opportu-
nity to request relevant information regarding the study
and decide on their own whether to participate in the
protocol. The protocol was approved by the local Ethics
and Scientific Committee of the Regina Elena Italian
National Cancer Institute (reference number IFO-84/
10). (The trial has been registered at the ClinicalTrials.
gov website and it is identified as NCT01316328).
Fibrosis was assessed using the National Cancer Insti-
tute’s Common Terminology Criteria for Adverse Events
(CTCAE, version 3.0) [31]. Fat necrosis was also scored
according to the system proposed by Lövely et al. [32].
The end-point of this study is Grade 2 or more fibrosis
or fat necrosis. Toxicity was defined as late if it occurred
≥ 6 months after radiotherapy.
All subjects enrolled in the study provided a blood
sample, approximately 5 ml, in sterile tubes containing
ethylenediaminetetracetic acid (EDTA). Whole blood
samples for DNA analyses were immediately frozen at
-80°C until processing. Total genomic DNA of samples
was extracted from blood leukocytes using the kit
QIAmp (DNA blood Mini Kit, Qiagen, Valencia, CA)
following the manufacturer’s instructions. DNA quality
was evaluated by spectrophotometer analysis (NanoDrop
instrument). PCR reactions for these polymorphic genes
were performed as Real Time PCR using Rotorgene
Instrument (Corbett) following PCR (Polymerase Chain
Reaction) conditions provided by the manufacturer’s
instructions. The polymorphic genes: XRCC3 C18067T
(Thr241Met), XRCC3 A4541G (5’-UTR untranslated
region), XRCC1 G28152A (Arg399Gln), GSTP1 A313G
(Ile105Val) RAD51 G135C (untranslated region includ-
ing in the commercial kits for Radiotherapy Response)
(Diatech company) were evaluated. The polymorphic
genes were analyzed using Pyrosequencing technologies
(instrument PyroMark MD-Biotage, Uppsala, Sweden)
according to a previously published method [33].
The first step of the study was designed to correlate
SNPs of genes and acute effects (i.e. erythema) [34]. We
assumed an erythema rate of 20% and 54% in patient
groups at low and high risk, respectively, (groups were
identified based on the absence/presence of the above
polymorphisms alone or in combination). Thus the
minimum sample size was 56 patients with a = 0.05, 2-
tailed test and a power of the study of 80%. More radio-
sensitive patients are expected to show an increased
number of acute, as well as, late effects. Thus, we also
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decided to investigate in a second step the late fibrosis/
fat necrosis and the following polymorphisms: XRCC3
C18067T (Thr241Met), XRCC3 A4541G (5’-UTR),
XRCC1 G28152A (Arg399Gln), GSTP1 A313G (Ile105-
Val) and RAD51 G135C (untranslated region). More-
over, we also analyzed combined genotypes according to
data from literature.
Tests for statistical significance were performed with
the chi-square and t-test for categorical and continuous
variables, respectively. Odds ratios (ORs) and 95% confi-
dence intervals (CIs), Chi-squared and Fisher exact (2-
sided) tests were calculated. An OR > 1.0 indicates an
increased risk of fibrosis in patients with polymorphic
gene. All tests were two-sided and considered to be sta-
tistically significant with a p-value of p = 0.05.
Results
To these study purposes, i.e. determining polymorph-
isms predicting late toxicity, we recruited 57 patients
treated with SSPBI from March 2006 to January 2008.
Out of 57 patients, 15 (26%) were also treated with
adjuvant non-concomitant chemotherapy. The adjuvant
chemotherapy had been completed 3-4 weeks before RT
with the exception of one patient (underwent che-
motherapy one-week after SSAPBI). Adjuvant hormo-
notherapy, as indicated, was given simultaneously with
SSPBI. Patient, tumour and treatment related character-
istics are listed in Table 1, respectively. In Table 2, we
reported the abbreviations for the polymorphic sites.
The genotyping procedure was successful in 57 patients.
The observed allele frequencies of the polymorphic
genes analyzed were comparable to those reported for
European populations in the dbSNP database and are
shown in Figure 1.
With a median follow-up 38 months (range: 19-50
months), the G1, G2 and G3 subcutaneous fibrosis, cor-
responding to a marked increased density and firmness
on palpation with/without retraction/fixation, were
observed in 23 (40%), 18 (32%) and 7 (12%) patients,
respectively. While the G2 and G3 fat necrosis were
observed in 1 (2%) and 1 (2%) patient, respectively.
Late moderate-to-severe (≥ G2) subcutaneous fibrosis
or fat necrosis were more frequent (64% vs 38%) in
patients with the mutation or heterozygote (aa/Aa)
genotype of GSTP1 (Ile105Val) with greater odds (OR =
2.9; 95% CI, 0.88-10.14, p = 0.047 Chi-square test).
No statistical significant increase/decrease of ORs was
observed with other SNPs or their combination. In par-
ticular, no correlation was found between late toxicity
and mut/het XRCC1 Arg399Gln, mut/het XRCC3
A4541G or mut/het XRCC3 Thr241Met or mut/het
RAD51. Table 3 shows a summary of a statistical
analysis.
Forest plots of ≥ G2 fibrosis or fat necrosis in breast
cancer patients against het/mut GSTP1 and XRCC1
Arg399Gln are shown in Figures 2 and 3, respectively,
reporting a meta-analysis of data available from
literature.
Discussion
Recently partial breast irradiation has been proposed in
a particular subgroup of patients at low risk of local
recurrence. In agreement with this approach, we tested
a new schedule at our Institute naming it SSPBI after
BCS [8,28]. Due to the major expected killing efficacy of
the single dose, unfortunately a incidence of fibrosis/fat
necrosis was observed in 44% of our patients.
Generally the moderate-to-severe fibrosis after con-
ventional fractionation is generally observed in 13.5%
[35] of patients at 10 years; thus a lot of patients to
obverse the same number of complications observed in
our cohort (44%). Moreover, the single dose is expected
to be more difficult to be repaired, enhancing the sce-
narios in which the mechanism of protect against ROS
damage or DNA repair fails.
It is for this reason, we focused our attention on SNPs
evaluation that may help design a clinical approach and
explain basic phenomena such as subcutaneous fibrosis
or fat necrosis. Fibrosis is a complex tissue response
characterized by a massive deposition of extra cellular
matrix (ECM) molecules (collagens, non collagenous
glycoproteins, glycosaminoglycans, proteoglycans) and
excessive fibroblast proliferation. Under oxidative stress
generated by ionization radiation, ROS levels can
increase dramatically, and this may result in significant
damage to cell structures. Accordingly, in the cellular
compartments, the response to oxidative stress can acti-
vate a series of processes including DNA repair, antioxi-
dant enzymes, cell cycle arrest and secretion of pro-
inflammatory cytokines such as TNF-a,TGF-b1,IL1, IL6
and many growth factors in the irradiated tissue. Some
authors reported that a coordinated cellular response
after radiation occurs, like the involvement antioxidant
enzymes (such as superoxide dismutases, catalases, lac-
toperoxidases, glutathione peroxidases and peroxiredox-
ins) to protect themselves against ROS damage [11-13].
Reduced mechanisms of cell protection resulting from
functional polymorphisms in several genes involved in
Table 1 Main patient and tumor characteristics
Age (years) median (range) 66 (51-87)
Tumor stage Tis/T1/T2 1/48/8
Nodal stage N0/N1 54/3
Chemotherapy yes/no 15/42
Hormone-therapy yes/no 52/5
Follow-up (months) median (range) 38 (19-50)
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these processes may be associated with the development
of late side effects following RT [36]. For these reasons,
we decided to investigate genetic variation in enzymes
involved in the detoxification process of oxidative stress
products, such as GSTP1, and its possible correlation
with susceptibility to late complications after RT [37,38].
In particular, we found that the polymorphic variant
(aa, Aa) of GSTP1 (Ile105Val), producing a protein with
reduced activity, is associated with higher risk of devel-
oping (G2 or more) a fibrosis or fat necrosis. In fact,
Forest plot shows behaviour as toxic agent for GSTP1.
The role of GSTP1 is debated in literature for example
Zschenker et al.[39] reported a no statistically significant
reduction in G2/G3 fibrosis (like-protective), Kuptsova
et al.[40], also in analyzing breast cancer patients found
no difference for fibrosis due to the relative small num-
ber of patients with this side effect. While Edvardsen et
al. [9] reported no association with fibrosis but with an
enhanced risk of pleural thickening (like-toxic).
In exacting, GSTP1 is involved in the regulation of cell
proliferation, apoptosis, stress response, phase II meta-
bolism, oncogenesis, tumour progression and drug resis-
tance. A number of recent studies [11-13] support the
role of GSTP1 in cell cycle control through the regula-
tion of c-Jun amino-terminal kinase (JNK) and its indir-
ect role in cellular signalling with interaction with
cellular proteins: TNF-a, TRAF2 cytochine, transcription
factor response gene AP-1.
As shown in Figure 4, under no stress condition
GSTP1 interacts with c-Jun amino-terminal kinases
(JNKs) and represses their activity. After treatment with
RT, the concentration of ROS in the cell increase and
causes the dissociation of GSTP1-JNK complex through
the oligomerization of GSTP1 from monomer to dimer.
Subsequently, the released JNK kinase recovers its func-
tional activity and can be phosphorylated and phosphor-
ylate c-jun. The consequent phosphorylation of c-jun
activates the transcription of AP-1 (stress responsive
Table 2 Polymorphism abbreviations
Gene NCBI
ds SNP ID
homozygote wt heterozygote Homozygote mut
XRCC1 G28152A (Arg399Gln) rs25487 GG (399 Arg/Arg) GA(399Arg/Gln) AA (399 Gln/Gln)
XRCC3 C18067T (Thr241Met) rs861539 CC (241Thr/Thr) CT(241Thr/Met) TT (241Met/Met)
XRCC3 A4541G (5’UTR) rs1799794 AA AG GG
GSTP1A313G (Ile105Val) rs1695 AA (105 Ile/Ile) AG (105 Ile/Val) GG (105 Val/Val)
RAD51 G135C (5’UTR) rs1801320 GG GC CC
Abbreviations: NCBI = National Center for Biotechnology Information, ID = identification
Figure 1 Polymorphism distribution.
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Table 3 ORs of ≥ G2 fibrosis or fat necrosis for different polymorphisms and their combination
Polymorphisms Genotype ≥ G2 fibrosis
or fat
necrosis
OR
(95% CI)
p-value (*) p-value (§)
XRCC1 (Arg399Gln) AA 45% 1
aa/Aa 54% 1.41 (0.44-4.58) 0.514 0.599
XRCC3(A4541G) aa/Aa 44% 1
AA 53% 1.43 (0.45-4.71) 0.494 0.596
XRCC3(C18067T) AA/Aa 51% 1
aa 33% 0.49 (0.04-3.75) 0.413 0.670
GSTP1 AA 38% 1
aa/Aa 64% 2.9 (0.88-10.14) 0.047 0.064
RAD51 AA 48% 1
aa/Aa 67% NA # 0.9751 0.6115
Abbreviations: (*) Chi-squared, (§) Fisher’s exact Test, #: not applicable due to the limited number of events
Figure 2 Forest plot summarizes a pooled analysis of G2 or more fibrosis/fat necrosis distinguishing patients with/without XRCC1
399Gln. The mutation is toxic or protective when OR is higher or lower than 1, respectively.
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factor) [41], that is involved in over expression of TGF-
b1 (Transforming Growth factor b1) at sites of RT-
induced injury. The critical role of TGF-b1 in beginning,
expansion and perseverance of fibrosis should be impor-
tant for preventing/reducing the radiation-induced
wound, also including loss of parenchymal cells and
excess of fibrous tissue. Furthermore, TGF-b1 modulates
the activities of cytochine, TNF-a (Tumour Necrosis
Factor alpha), basic fibroblast growth factor (bFGF),
granulocyte macrofage colony-stimulating factor (GM-
CFS) IL-1, IL-4(interleukins) and connective tissue growth
factor (CTGF) that are deregulated after radiation
[42-45]. Thus, this figure suggests that GSTp1 could be
indirectly correlated with the regulation of TGF-b1 by
the AP-1 path [46,47].
In accordance with our data, we speculate that the
occurrence of fibrosis observed in our cohort of patients
may be correlated to the altered regulation of TGF-b1
induced by GSTP1 105Val polymorphic variant. In this
connection, it will be of interest to address this important
issue in future studies evaluating the expression levels of
TGF-b1 in patients bearing GSTP1 polymorphism.
In this same cohort of patients, we also evaluated the
effects of polymorphism encoding enzymes involved in
Figure 3 Forest plot summarizes a pooled analysis of G2 or
more fibrosis/fat necrosis distinguishing patients with/without
het/mut GSTP1. The mutation is toxic or protective when OR is
higher or lower than 1, respectively.
Figure 4 GSTP1 rule in stress response system.
Falvo et al. Journal of Experimental & Clinical Cancer Research 2012, 31:7
http://www.jeccr.com/content/31/1/7
Page 6 of 9
DNA repair, such as XRCC1 and XRCC3, in relation to
fibrosis or fat necrosis. In fact, the cellular pathways of
DNA repair more involved in the response to radiation
injury are DSBR and BER In vitro and in vivo studies
have shown that polymorphisms of genes involved in
these two mechanisms of DNA repair may influence the
cellular sensitivity to RT [48-50]. Our results showed no
significant association between XRCC3 C18067T and
radio-sensitivity in agreement with studies by Andreas-
sen et al. and Chang-Claude et al. [51-53] in breast can-
cer patients or by Alsbeish et al. in head and neck
cancer patients [54].
An association between wild type XRCC3 C18067 and
an increased rate of late toxic effects, such as subcuta-
neous fibrosis, were found in breast cancer [55] and
prostate [56].
No statistical significant association between XRCC1
Arg399Gln and radio-sensitivity was found in our study, as
well as in other studies [17,19,57]. However, Forest plot
showed a behaviour as toxic agent of mut/het XRCC1
Arg399Gln in agreement with an increased rate of lung
effects in non small cell lung cancer patients. [58].
Finally, no correlation was found between late toxicity
mut/het XRCC3 A4541G and mut/het RAD51.
Our low correlation between incidence of G2 or more
fibrosis or fat necrosis and alleles/patient is probably
due to the low number of patients with G2 or more
fibrosis or fat necrosis. Another issue to consider is that
in comparison of other findings some differences are
expected due to the types of adverse reactions studied,
the length of follow-up for observing side effects, as well
as, the additional patient-related factors.
Conclusions
The presence of some SNPs involved in DNA repair or
response to oxidative stress seem to be able to predict
late toxicity. This study, although affected by a limited
number of patients, has a power of the study statistically
sufficient to suggest that SNP in GSTP1 gene could be
useful to predict late toxicity in BC patients who under-
went SSPBI. Further data are needed to confirm these
preliminary results. Moreover, future research will focus
on the performance of many additional SNPs in other
genes that are associated with the development of radia-
tion toxicity.
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